Phase II Study of 2-Chlorodeoxyadenosine (2CDA) Followed By Rituximab in Hairy Cell Leukemia
Cladribine is a chemotherapy drug that has been used for over 10 years to treat HCL with
very good results and very low rate of side effects. Rituximab is an antibody protein that
targets a specific molecule on the surface of cancer cells in order to eliminate them. It
has been used for over 5 years to treat a number of cancers of blood and lymph nodes and has
been used with some success to treat patients with HCL whose disease has returned after a
If you are found to be eligible to take part in this study, you will receive cladribine by
vein over 2 hours once a day for 5 days in a row. You will only receive 1 cycle (5 days) of
this treatment. Then you will receive rituximab by vein once a week for 8 weeks. Treatment
with rituximab will start around Day 28.
After the first dose of each study drug has been given to you at MD Anderson, all later
doses of both drugs can be given to you by your community doctor in your home town. You
will have a weekly blood tests (about 1 teaspoon each) for the first 4 weeks and before
receiving rituximab. You will have a repeat bone marrow biopsy before starting rituximab in
order to see how much disease is left behind. You will then have a blood test (about 1
teaspoon) every 2 to 4 weeks while you are receiving rituximab. A bone marrow biopsy will
also be done at the end of rituximab treatment.
You will be taken off the study if the disease gets worse or if intolerable side effects
occur. After completing rituximab, you will return for a follow-up visit every 3 months for
one year. At these visits you will have blood (about 1 teaspoon) tests performed.
This is an investigational study. Both drugs are approved by the FDA and are commercially
available. Their use together in this study, however, is experimental. A total of 74
patients will take part in this study. All will be enrolled at MD Anderson.
Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
Farhad Ravandi-Kashani, MD
M.D. Anderson Cancer Center
United States: Food and Drug Administration
|UT MD Anderson Cancer Center||Houston, Texas 77030|